Development of the Danish Prospective Sarcoidosis Registry and Baseline Characteristics of a Danish Sarcoidosis Cohort

Development of a Danish Sarcoidosis Registry. Characterization of a cohort of sarcoidosis patients with respect to the baseline epidemiological characteristics, comorbidities, radiology, histopathology, diagnostic investigations and treatment.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Sarcoidosis Hemic and Lymphatic Diseases Hypersensitivity Hypersensitivity, Delayed Immune System Diseases Lymphatic Diseases Lymphoproliferative Disorders

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Aarhus University Hospital

Aarhus N, 8200, Denmark

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Diagnosis of sarcoidosis
Signed informed consent

Exclusion criteria

Inability or unwillingness to adhere to the study
Inability to give informed consent

Treatment and study plan

Primary outcomes

Characterization of Danish sarcoid patients

Time frame: 2 years

Epidemiology and Baseline characteristics of a Danish Sarcoidosis Cohort
Feasibility and completion of a Sarcoidosis Registry.

Time frame: 2 years

Development of a Danish sarcoidosis registry Data on epidemiology, clinical characteristics, diagnosis and management will be registered

Sponsors and collaborators

Lead sponsor

University of Aarhus

Other

Registry information

Important dates

Study start: 2019
Primary completion: 2022
Study completion: 2022
First posted: May 14, 2020
Registry last updated: Jun 6, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed